• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Verrica Pharmaceuticals Inc. - Common Stock (NQ:VRCA)

    4.030 -0.060 (-1.47%)
    Streaming Delayed Price Updated: 9:35 AM EDT, Sep 26, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,912
    Open 4.060
    Bid (Size) 4.050 (10)
    Ask (Size) 4.220 (1)
    Prev. Close 4.090
    Today's Range 4.000 - 4.060
    52wk Range 3.816 - 17.70
    Shares Outstanding 41,957,197
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Top movers in Friday's pre-market session
    Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
    Via Chartmill
    12 Health Care Stocks Moving In Friday's Pre-Market Session
     
    Via Benzinga

    Performance

    YTD
    -42.6%
    -42.6%
    1 Month
    -32.5%
    -32.5%
    3 Month
    -30.8%
    -30.8%
    6 Month
    -7.9%
    -7.9%
    1 Year
    -75.7%
    -75.7%

    More News

    Read More
    Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    What to Expect from Verrica Pharmaceuticals's Earnings
    Via Benzinga
    Earnings Outlook For Verrica Pharmaceuticals
    Via Benzinga
    Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Posts Profit in Fiscal Q2
    Via The Motley Fool
    Topics Intellectual Property
    Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Earnings Scheduled For August 12, 2025
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Earnings Scheduled For May 13, 2025
    Via Benzinga
    Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Verrica Pharmaceuticals Inc. - Common Stock publicly traded?
    Yes, Verrica Pharmaceuticals Inc. - Common Stock is publicly traded.
    What exchange does Verrica Pharmaceuticals Inc. - Common Stock trade on?
    Verrica Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock?
    The ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock is VRCA on the Nasdaq Stock Market
    What is the current price of Verrica Pharmaceuticals Inc. - Common Stock?
    The current price of Verrica Pharmaceuticals Inc. - Common Stock is 4.030
    When was Verrica Pharmaceuticals Inc. - Common Stock last traded?
    The last trade of Verrica Pharmaceuticals Inc. - Common Stock was at 09/26/25 09:35 AM ET
    What is the market capitalization of Verrica Pharmaceuticals Inc. - Common Stock?
    The market capitalization of Verrica Pharmaceuticals Inc. - Common Stock is 169.09M
    How many shares of Verrica Pharmaceuticals Inc. - Common Stock are outstanding?
    Verrica Pharmaceuticals Inc. - Common Stock has 169M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.